Cent Eur J Public Health 2022, 30(Supplement):S22-S26 | DOI: 10.21101/cejph.a6809

Long-term compliance of patients with osteoporosis treatment and its effect to fracture occurrence

Róbert Čellár1, Erik Dorko2, Kvetoslava Rimárová2, Matúš Bereš1, David Sokol1, Ahmad Gharaibeh1, Martin Folvarský1, István Mitró1, Viliam Knap3
1 Department of Orthopaedics and Traumatology of Locomotory Apparatus, Faculty of Medicine, Pavol Jozef Šafárik University and Louis Pasteur University Hospital in Košice, Košice, Slovak Republic
2 Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic
3 Department of Physiatry, Balneology and Medical Rehabilitation, Faculty of Medicine, Pavol Jozef Šafárik University and Louis Pasteur University Hospital in Košice, Košice, Slovak Republic

Objectives: The objective of this study was to evaluate the effect of long-term treatment of patients with osteoporosis being actively managed by medical staff and following the therapeutic methods and principles of treatment of osteoporosis.

Methods: The medical records of patients which were examined in an osteological outpatient office first time in the year 2009 were reviewed. The results of densitometry examinations were compared with the results from the year 2019. Patients regularly absolved densitometry, properly and regularly took prescribed medicaments for either anti-osteoporotic treatment or for supplementation of vitamin D and calcium. The cohort consisted of 100 patients. Next, we split the group into 3 categories - less than 65 years of age, 65-75 years of age and lastly over 75 years of age. By default, we assessed and compared the T-scores (deviation from the average value of bone density of 30 years old healthy person) in the area of the proximal femur and in the area of the lumbar spine. The bone mineral density (BMD) values in g/cm2 and their relation to corresponding T-score from set area were also reviewed.

Results: Based on the results of densitometry, osteoporosis was diagnosed in 41 patients, manifest osteoporosis in 14 and osteopenia in 36, nine patients had their bone density value within the normal range. The average T-score values of "total hip" were -1.42, "neck" -2.08, BMD values of "total hip" were 0.802 g/cm2, "L1-L4" -2.05, "L total" -1.45, and BMD of "L total" was 0.886 g/cm2. In the time of the last examination, the T-score (disregarding the type of treatment) raised from the initial value by 40.16% in the area of lumbar spine, by 56.69% in the area of "total hip", and by 40.16% in the area of "neck". While sorting the cohort based on age, we detected a similar effect of active management of treatment in each of the 3 categories.

Conclusion: Cooperation of the patients during the treatment of a chronic disease requiring long-term usage of medicaments is often problematic and it is necessary to devote adequate attention to it. The solution to improve the treatment can be active management of the patient by the medical facility or by the medical staff.

Keywords: osteoporosis, osteoporosis treatment, compliance

Received: February 20, 2021; Revised: January 10, 2022; Accepted: January 10, 2022; Published: June 27, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čellár R, Dorko E, Rimárová K, Bereš M, Sokol D, Gharaibeh A, et al.. Long-term compliance of patients with osteoporosis treatment and its effect to fracture occurrence. Cent Eur J Public Health. 2022;30(Supplement):S22-26. doi: 10.21101/cejph.a6809. PubMed PMID: 35841221.
Download citation

References

  1. Payer J, Killinger Z, Jackuliak P, Tomková S, Baňárová A, Brázdilová K, et al. Osteoporosis. Bratislava: Herba; 2012. (In Slovak.)
  2. Payer J, Killinger Z, Lalciková E. Diagnostics of osteoporosis. Via Pract. 2013;10(3/4):92-94. (In Slovak.)
  3. Koelé MC, Lems WF, Willems HC. The clinical relevance of hyperkyphosis: a narrative review. Front Endocrinol (Lausanne). 2020;11:5. doi: 10.3389/fendo.2020.00005. Go to original source... Go to PubMed...
  4. Payer J, Brázdilová K, Jackuliak P, Killinger Z. Osteoporosis pharmacotherapy and adherence of patient. Via Pract. 2010;7(5):202-6. (In Slovak.)
  5. Fatoye F, Smith P, Gebrye T, Yeowell G. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019;9(4):e027049. doi: 10.1136/bmjopen-2018-027049. Go to original source... Go to PubMed...
  6. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82(12):1493-501. Go to original source...
  7. Payer J, Killinger Z, Šulková I, Celec P. Therapeutic adherence to bisphosphonates. Biomed Pharmacother. 2007;61(4):191-3. Go to original source... Go to PubMed...
  8. Expert recommendation for osteoporosis diagnostics and treatment. Vestník MZ SR. 2006;54(9-16):24. (In Slovak.)
  9. Cauley JA. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci. 2013;68(10):1243-51. Go to original source... Go to PubMed...
  10. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-75. Go to original source... Go to PubMed...
  11. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The associations of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Mang Care Pharm. 2011;17(1):25-39. Go to original source... Go to PubMed...
  12. Nguyen VH. Osteoporosis prevention and osteoporosis exercise in community-based public health programs. Osteoporos Sarcopenia. 2017;3(1):18-31. Go to original source... Go to PubMed...
  13. Morley J, Moayyeri A, Ali L, Taylor A, Feudjo-Tepie M, Hamilton L, et al. Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int. 2020;31(3):533-45. Go to original source... Go to PubMed...
  14. Park JH, Park EK, Koo DW, Lee S, Lee SH, Kim GT, et al. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2017;18(1):152. doi: 10.1186/s12891-017-1514-4. Go to original source... Go to PubMed...
  15. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271-87. Go to original source... Go to PubMed...
  16. Silverman SL, Siris E, Belazi D, Recknor C, Papaioannou A, Brown JP, et al. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. Arch Osteoporos. 2018;13(1):85. doi: 10.1007/s11657-018-0491-z. Go to original source... Go to PubMed...
  17. Cornelissen D, de Kunder S, Reginster JY, Evers S, Boonen A, Hiligsmann M; European Society for Clinical and Economic Aspect of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int. 2020;31(9):1645-69. Go to original source... Go to PubMed...
  18. Jaleel A, Saag KG, Danila MI. Improving drug adherence in osteoporosis: an update on more recent studies. Ther Adv Musculoskelet Dis. 2018;10(7):141-9. Go to original source... Go to PubMed...
  19. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-23. Go to original source... Go to PubMed...
  20. Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317-26. Go to original source... Go to PubMed...